Miconazole%2525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%2525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole vaginal pessary ## Overview Miconazole is a broad-spectrum antifungal agent. Vaginal pessaries are designed for local treatment of vaginal yeast infections. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infection). ## Adult Dosing * **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 days. * **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 days. * **1500 mg pessary:** Insert one single-dose pessary vaginally at bedtime. ## Pediatric Dosing Data on pediatric use of miconazole vaginal pessaries is limited. Consult with a pediatrician or local protocol for appropriate dosing in pediatric patients. ## Dose Adjustments No dose adjustments are typically required for hepatic or renal impairment due to minimal systemic absorption. ## Contraindications * Known hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects Commonly reported adverse effects include vaginal burning, itching, irritation, and lower abdominal cramping. Allergic reactions are possible. ## Key Drug Interactions * **Warfarin:** Miconazole (especially oral formulations, but caution with vaginal) can inhibit CYP2C9, potentially increasing warfarin levels and INR. Monitor INR closely if coadministered. * **CYP3A4 Substrates:** Miconazole can inhibit CYP3A4. Systemic absorption is low with vaginal pessaries, but drug interactions are theoretically possible with highly dependent CYP3A4 substrates, especially with prolonged or extensive use. ## Monitoring * Monitor for signs and symptoms of recurrent or persistent infection. * Monitor for adverse effects. * If co-prescribing with warfarin, monitor INR. ## Clinical Pearls * Complete the full course of treatment even if symptoms improve earlier. * Avoid intercourse during treatment. * Oily or latex products (condoms, diaphragms) may be damaged by the pessary base, leading to contraceptive failure or increased risk of STIs. Advise patients to use alternative methods of contraception and barrier protection during and for at least 72 hours after treatment. * If symptoms do not improve after completing therapy, re-evaluate the diagnosis and consider alternative antifungal agents. *** **Disclaimer:** This information is intended for healthcare professionals. Always verify current prescribing information with the official product labeling and consult institutional protocols, as recommendations may vary.